Logo image
Liquid biopsy-based detection of circulating and exfoliated cholangiocarcinoma tumor cells from blood and bile using heparan sulfate octasaccharides on integrated microfluidic systems
期刊文章   同儕審查

Liquid biopsy-based detection of circulating and exfoliated cholangiocarcinoma tumor cells from blood and bile using heparan sulfate octasaccharides on integrated microfluidic systems

Wei-Chun Tsai, Anandaraju Bandaru, Cheng-Hsiu Chang, Priya Gopinathan, Chih-Hung Wang, Yi-Cheng Tsai, Chien-Jui Huang, Nai-Jung Chiang, Yu-Jie Huang, Yan-Shen Shan, …
Methods (San Diego, Calif.), 卷.255, 頁碼.62-72
01/11/2026
PMID: 42633865
Web of Science ID: WOS:001860464500001

摘要

Cholangiocarcinoma Circulating tumor cells Exfoliated tumor cells Heparan sulfate octasaccharide Integrated microfluidic system Liquid biopsy
•A standardized liquid biopsy workflow for cholangiocarcinoma tumor-cell detection is presented.•Heparan sulfate octasaccharides enable tumor-cell enrichment from blood and bile samples.•Integrated microfluidic platforms automate sample processing and cell identification.•The workflow supports reproducible enrichment of rare tumor cells from clinical specimens. Early diagnosis of cholangiocarcinoma (CCA) remains challenging because existing diagnostic approaches often lack sufficient sensitivity for reliable detection of early-stage disease. Circulating tumor cells (CTCs) in blood and exfoliated tumor cells (ETCs) in bile represent valuable targets for liquid biopsy-based detection; however, their low abundance and the complexity of clinical sample analysis pose substantial technical challenges for reliable enrichment and identification. Herein, we present a reproducible workflow for isolating and identifying CCA tumor cells from blood for CTCs and bile for ETCs using synthetic cell-surface heparan sulfate (HS) octasaccharide-functionalized magnetic beads (MBs) on integrated microfluidic systems. The method combined sample pre-processing, magnetic bead-based enrichment, controlled low-shear mixing and immunofluorescence-based identification into a unified workflow compatible with distinct clinical sample types. Key operational parameters, including MB concentration, mixing frequency, and pressure settings, were detailed to facilitate consistent performance. Using this workflow, tumor cell capture rates of approximately 70% in bile (for ETCs) and blood (for CTCs) were achieved, with a total processing time of 60–90 min per sample under clinically relevant low-abundance conditions. The platform enables reliable detection of as few as 1 tumor cell per mL of blood or bile. This method provides a practical and adaptable strategy for glycosaminoglycan-mediated liquid biopsy applications and may be extended to other tumor-cell enrichment workflows involving heterogeneous cell-surface interactions.

相關連結

指標

1 檢視次數

詳細資料

Logo image